Medicinal by Presentation: Why How You Say Something Matters as Much as What You Sell

Most supplement compliance conversations focus on ingredients: is this dose legal, does this claim have EFSA authorization. That's necessary, but it's only half the picture. Under EU law, a product can become an unauthorized medicinal product — regardless of what's actually in it — purely because of how it is marketed. This is the “medicinal by presentation” doctrine, and it's stricter, and more commonly triggered, than most brands assume.

The two ways a product can become “medicinal” under EU law

Directive 2001/83/EC defines a medicinal product two separate ways, and a product only needs to meet one of them to be classified as medicinal:¹²

1. Medicinal by function — the product actually has a pharmacological, immunological, or metabolic effect that treats, prevents, or diagnoses disease.
2. Medicinal by presentation — the product is presented as having properties for treating or preventing disease, regardless of whether it actually has that effect.

The second limb is the trap. It means a product with a completely legal ingredient list — vitamins, minerals, botanicals, all within permitted doses — can still be reclassified as an unauthorized medicine based purely on its marketing language, imagery, or implied claims. Composition doesn't save you if presentation crosses the line.

What “presentation” actually covers

This isn't limited to a single explicit sentence like “cures your illness.” EU case law and national enforcement look at the overall impression a product creates, including:³⁴

• Product name or naming conventions that imply a therapeutic function (e.g., naming a formula after a medical condition or a physiological “axis” it claims to support)
• Packaging, imagery, or design cues that resemble pharmaceutical products
• Testimonials or before/after framing that imply disease treatment or symptom resolution
• Surrounding marketing copy — website content, social posts, influencer briefs — that attributes disease-related benefits, even if the product label itself is compliant
• Comparisons to medications or implied substitution for prescribed treatment

Critically, the assessment is holistic. A perfectly compliant product page can still trip this doctrine if the blog post linking to it, the ad copy driving traffic to it, or an affiliate's video about it makes disease-related claims the brand didn't put on the label itself. Enforcement doesn't stop at the product page.

The legal precedent: Hecht-Pharma

The clearest guidance on where the line sits comes from the European Court of Justice's 2009 Hecht-Pharma ruling, involving a red yeast rice supplement that German authorities had classified as an unauthorized medicine.²⁵ The ECJ ruled that pharmaceutical law applies only to products sold for the treatment, cure, or prevention of human disease, or which are scientifically proven, by their composition, to modify physiological functions — and that this classification must be made case-by-case, based on the product's actual pharmacological properties and its presentation, not assumed from ingredient category alone.² The ruling reinforced that the definition of “medicinal product” should be interpreted narrowly, giving food-supplement makers more legal certainty — but only for products whose presentation doesn't independently invite medicinal classification.²

Why this matters more for supplement brands than most realize

Two structural features of EU enforcement make this doctrine especially consequential:

• Member states can and do disagree. The same product, with the same label, can be treated as a food supplement in one EU country and a medicinal product in another, because national competent authorities apply the case-by-case test independently.³⁶ A brand operating across Slovakia, Czechia, and the DACH region can't assume a classification that's safe in one market automatically holds in another.
• Enforcement isn't limited to the label.Real-world consequences cited by EU regulatory practitioners include border detentions by customs authorities, market withdrawal orders from national bodies (e.g., Germany's BVL, France's DGCCRF), and in some cases legal proceedings — often triggered not by the product formulation itself but by claims made in marketing material surrounding it.⁶

The practical takeaway

The safest posture for a marine-sourced, clinically formulated supplement brand is to treat every piece of customer-facing content — not just the product label — as part of the presentation the “medicinal by presentation” test will evaluate. That means:

• Anchoring claims to structure/function language (“supports normal X,” using only EFSA-authorized wording where a claim is made) rather than disease-outcome language (“treats X,” “cures Y,” “reverses Z”)
• Avoiding product or formula names that reference a medical condition, diagnosis, or disease state
• Keeping surrounding content — blog posts, ads, influencer briefs — as disciplined about this line as the product page itself, since regulators evaluate the whole picture
• Recognizing that “borderline” is a real, named legal category — not just marketing caution — and that a case-by-case test means no single rule of thumb (like “never say cure”) fully insulates a brand, since imagery, naming, and implied comparison all count too

Composition compliance and claim compliance are necessary. Presentation discipline is what closes the remaining gap.